image
imagewidth (px) 200
7.07k
| image_filename
stringlengths 64
64
| query
stringlengths 37
199
| answer
stringlengths 2
187
| source
stringclasses 1
value |
---|---|---|---|---|
54d13dce165b5644291f8754358d1de448531b044d1bf782719a486b93efba26
|
What are mixed with α, γ?
Keep it short and to the point.
|
Α, γ.
|
docvqa
|
|
54d13dce165b5644291f8754358d1de448531b044d1bf782719a486b93efba26
|
What are the renal effects mentioned?
Provide a succinct answer.
|
Urine electrolytes, osmolality, ph.
|
docvqa
|
|
909f9df1cac97530c056fa33c32531f586025dba335771caa0e3c4944adc7464
|
From whom has this email been sent?
Your answer should be very brief.
|
Kanayama Kiyoshi.
|
docvqa
|
|
909f9df1cac97530c056fa33c32531f586025dba335771caa0e3c4944adc7464
|
Who are on the CC list?
Give a very brief answer.
|
Shephard, Kirk (TPI); Fuse, Touichirou (TPC).
|
docvqa
|
|
909f9df1cac97530c056fa33c32531f586025dba335771caa0e3c4944adc7464
|
What is the email ID of Kanayama Kiyoshi?
Offer a terse response.
|
docvqa
|
||
909f9df1cac97530c056fa33c32531f586025dba335771caa0e3c4944adc7464
|
What is the subject of this email?
Your answer should be compact.
|
Re: Potential Publicaton in Correspondence Section of The Lancet.
|
docvqa
|
|
f910268745f57cbd7d92e1df199f6cc21d32693bc8e8f36b1fe94cc2b180963b
|
What is the level of importance of the email send by Witte, Kimberly?
Offer a terse response.
|
High.
|
docvqa
|
|
f910268745f57cbd7d92e1df199f6cc21d32693bc8e8f36b1fe94cc2b180963b
|
What is the subject of the document?
Offer a very short reply.
|
FW: SKB PROBLEMS.
|
docvqa
|
|
f910268745f57cbd7d92e1df199f6cc21d32693bc8e8f36b1fe94cc2b180963b
|
What is the EXHIBIT number mentioned?
Make the answer very short.
|
9.
|
docvqa
|
|
f910268745f57cbd7d92e1df199f6cc21d32693bc8e8f36b1fe94cc2b180963b
|
What is the exhibit no given in the document?
Your response must be concise.
|
9.
|
docvqa
|
|
97bb6611094f59a671d6537fa05751a69e133f6798adc47058037c39950952e3
|
Who is this Memo to?
Ensure brevity in your answer.
|
Distribution.
|
docvqa
|
|
97bb6611094f59a671d6537fa05751a69e133f6798adc47058037c39950952e3
|
What is the date mentioned?
Keep it short and to the point.
|
July 19, 2002.
|
docvqa
|
|
97bb6611094f59a671d6537fa05751a69e133f6798adc47058037c39950952e3
|
Whose signature is present at the bottom?
Your response must be concise.
|
MARLENE C. DUBAS.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
Who are in the cc?
Your answer should be compact.
|
Johnston,kendra; precurato-grubb, marti.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
What is the "subject" of this letter?
Give a very brief answer.
|
Article in today's usa today regarding avandia hearing.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
Who is writing this letter?
Keep it short and to the point.
|
Gigi m. chen, mba.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
When was this letter sent?
Provide a succinct answer.
|
7/31/2007 11:48:09 am.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
Who is the premier sales representative ?
Keep it short and to the point.
|
Gigi m. chen, mba.
|
docvqa
|
|
ed655468bd5d471b353289ce58f822065e87a33d40b8ae1b666fe2147bdb693b
|
What is the cellular number of Gigi M. Chen?
Your answer should be very brief.
|
716.725.7100.
|
docvqa
|
|
d9a76296211efc52576f430d50a2da518878e71f318195be0b5173ec0498d30d
|
Who is the 23rd Addressee mentioned in the list?
Keep it short and to the point.
|
Senior Vice President, Accounting Center.
|
docvqa
|
|
416334fd45e5804a318cc661ddf4a93d838a02cde5a9915971ce7a1e5d1c4a8d
|
Heading of the document?
Your answer should be very brief.
|
Draft Agenda.
|
docvqa
|
|
416334fd45e5804a318cc661ddf4a93d838a02cde5a9915971ce7a1e5d1c4a8d
|
What are the timings for Continental Breakfast?
Ensure brevity in your answer.
|
8:00-9:00.
|
docvqa
|
|
481a58cbd483d9cb9b305eea86c940c1dad1ab77275d7109b0cbc86231d55bbe
|
What is the title of this page?
Your answer should be very brief.
|
Executive summary, cont.
|
docvqa
|
|
481a58cbd483d9cb9b305eea86c940c1dad1ab77275d7109b0cbc86231d55bbe
|
What is the first point under the title-executive summary, cont.
Provide a succinct answer.
|
Proposed experiments.
|
docvqa
|
|
3c6c521849fd2a73f9455573b472ab444f8847dda1e4687e3fe9f58b921e741f
|
Heading of the document?
Give a very brief answer.
|
Response Document.
|
docvqa
|
|
59b56048360ab5a841c5bd9a1af351a278f62154a2144db79585f4f0980da6aa
|
What is the full form of FDA?
Ensure brevity in your answer.
|
Food and Drug Administration.
|
docvqa
|
|
59b56048360ab5a841c5bd9a1af351a278f62154a2144db79585f4f0980da6aa
|
What is the date mentioned?
Offer a very short reply.
|
January 3, 2003.
|
docvqa
|
|
59b56048360ab5a841c5bd9a1af351a278f62154a2144db79585f4f0980da6aa
|
Who is the sender of this fax?
Your response must be concise.
|
Jena Weber.
|
docvqa
|
|
59b56048360ab5a841c5bd9a1af351a278f62154a2144db79585f4f0980da6aa
|
What is the total no of pages in the fax including cover?
Provide a succinct answer.
|
1.
|
docvqa
|
|
8ab6ecc6b0787812deccb2640381c6440cdf2e80665b3cafd35e05dc3a523d66
|
Who is writing this letter?
Your response must be concise.
|
Marlene dubas.
|
docvqa
|
|
8ab6ecc6b0787812deccb2640381c6440cdf2e80665b3cafd35e05dc3a523d66
|
Who is in the cc?
Ensure brevity in your answer.
|
Tom muldoon.
|
docvqa
|
|
8ab6ecc6b0787812deccb2640381c6440cdf2e80665b3cafd35e05dc3a523d66
|
Which all compaies are added as defendants in a lawsuit?
Provide a succinct answer.
|
Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals America, Inc.
|
docvqa
|
|
8ab6ecc6b0787812deccb2640381c6440cdf2e80665b3cafd35e05dc3a523d66
|
What is 're' in the letter?
Offer a very short reply.
|
Preservation of documents and electronic data relating to actos.
|
docvqa
|
|
2d6170bee3499e4b3c85f5efc1c34f53b57c9f6fb7b042275a7ea874579a3d52
|
Heading of the first paragraph?
Offer a terse response.
|
SIXTH OBJECTION.
|
docvqa
|
|
2d6170bee3499e4b3c85f5efc1c34f53b57c9f6fb7b042275a7ea874579a3d52
|
Name of the judge?
Ensure brevity in your answer.
|
Patrick Hanna.
|
docvqa
|
|
2d6170bee3499e4b3c85f5efc1c34f53b57c9f6fb7b042275a7ea874579a3d52
|
What is the page no mentioned in this document?
Offer a terse response.
|
3.
|
docvqa
|
|
2d6170bee3499e4b3c85f5efc1c34f53b57c9f6fb7b042275a7ea874579a3d52
|
When was the hearing before Judge?
Your answer should be compact.
|
July 25, 2013.
|
docvqa
|
|
3764f6f24c3155d2102b49b2fd76772cf5e853305e19a10a8a41ca19e4e5e7af
|
What is the date mentioned?
Keep it short and to the point.
|
January 14, 1999.
|
docvqa
|
|
3764f6f24c3155d2102b49b2fd76772cf5e853305e19a10a8a41ca19e4e5e7af
|
What is the company name ?
Offer a very short reply.
|
ELI LILLY AND COMPANY.
|
docvqa
|
|
3764f6f24c3155d2102b49b2fd76772cf5e853305e19a10a8a41ca19e4e5e7af
|
Which benefit start after 1 year of service?
Give a very brief answer.
|
Extended Disability.
|
docvqa
|
|
fcb04dc2b25fd4d24fe5a3274a0adfbe4585858315234e49582d0b7f23878b0b
|
What is the name of the company mentioned in the letterhead?
Your answer should be compact.
|
DEPARTMENT OF HEALTH & HUMAN SERVICES.
|
docvqa
|
|
fcb04dc2b25fd4d24fe5a3274a0adfbe4585858315234e49582d0b7f23878b0b
|
What is the fullform of NDA?
Make the answer very short.
|
New drug application.
|
docvqa
|
|
fcb04dc2b25fd4d24fe5a3274a0adfbe4585858315234e49582d0b7f23878b0b
|
What is the name of the addressee?
Your response must be concise.
|
Ms. Pritza.
|
docvqa
|
|
fcb04dc2b25fd4d24fe5a3274a0adfbe4585858315234e49582d0b7f23878b0b
|
What kind of a letter is this ?
Your answer should be very brief.
|
DISCIPLINE REVIEW LETTER.
|
docvqa
|
|
fcb04dc2b25fd4d24fe5a3274a0adfbe4585858315234e49582d0b7f23878b0b
|
When did Regulatory affairs department receive this letter?
Provide a succinct answer.
|
Feb 19 2007.
|
docvqa
|
|
b7787080c9e5a23fcd21261271807e07d1a6f2e25aad2b21f1263b1a0779c3f5
|
What is the date mentioned?
Offer a very short reply.
|
August 16, 1999.
|
docvqa
|
|
b7787080c9e5a23fcd21261271807e07d1a6f2e25aad2b21f1263b1a0779c3f5
|
To whom is this letter addressed?
Provide a short and direct response.
|
Alan D. Mackenzie.
|
docvqa
|
|
b7787080c9e5a23fcd21261271807e07d1a6f2e25aad2b21f1263b1a0779c3f5
|
What is the full form of TPA?
Ensure brevity in your answer.
|
Takeda Pharmaceuticals America, Inc.
|
docvqa
|
|
b7787080c9e5a23fcd21261271807e07d1a6f2e25aad2b21f1263b1a0779c3f5
|
Which two companies have agreed to amend the Co-Promotion Agreement?
Ensure brevity in your answer.
|
Takeda Pharmaceuticals America, Inc. ("TPA") and Eli Lilly and Company ("Lilly").
|
docvqa
|
|
6eaa96355a090a110138ba454368ba58b8775fe38da5c8e1f2aa85e9eb0cc2c8
|
What is the name of the company?
Give a very brief answer.
|
THE UPJOHN COMPANY.
|
docvqa
|
|
6eaa96355a090a110138ba454368ba58b8775fe38da5c8e1f2aa85e9eb0cc2c8
|
What is the date mentioned?
Give a very brief answer.
|
September 21, 1993.
|
docvqa
|
|
6eaa96355a090a110138ba454368ba58b8775fe38da5c8e1f2aa85e9eb0cc2c8
|
To whom is this letter addressed?
Provide a short and direct response.
|
Doctor Matsuzawa.
|
docvqa
|
|
6eaa96355a090a110138ba454368ba58b8775fe38da5c8e1f2aa85e9eb0cc2c8
|
As a consequence of the decision Upjohn must decline participation with which company?
Give a very brief answer.
|
Takeda.
|
docvqa
|
|
3fbf1c8b4c7f829fcab5300492268152bb57c41e17d936b8525270c06d1200c1
|
A 79-year-old female was enrolled in the study for how many days?
Your answer should be very brief.
|
200 days.
|
docvqa
|
|
3fbf1c8b4c7f829fcab5300492268152bb57c41e17d936b8525270c06d1200c1
|
The patient had a history of bladder cancer since when?
Ensure brevity in your answer.
|
Since 1996.
|
docvqa
|
|
3fbf1c8b4c7f829fcab5300492268152bb57c41e17d936b8525270c06d1200c1
|
Who is the writer of the document?
Ensure brevity in your answer.
|
Janet L. Haskins.
|
docvqa
|
|
3fbf1c8b4c7f829fcab5300492268152bb57c41e17d936b8525270c06d1200c1
|
The woman had a positive history of what?
Provide a short and direct response.
|
Tobacco use.
|
docvqa
|
|
33ca981684f22d045dd7c064c0d26f2f3b5581b57177f62bfb364007236a73fe
|
Who is the general manager of International development Dept. of Takeda Chemical Industires, Ltd.?
Give a very brief answer.
|
K. Kitazawa, Ph. D.
|
docvqa
|
|
33ca981684f22d045dd7c064c0d26f2f3b5581b57177f62bfb364007236a73fe
|
What is the name of the industry ?
Offer a terse response.
|
TAKEDA CHEMICAL INDUSTRIES , LTD .
|
docvqa
|
|
33ca981684f22d045dd7c064c0d26f2f3b5581b57177f62bfb364007236a73fe
|
How many pages are there in total?
Offer a terse response.
|
Page 2 of 2.
|
docvqa
|
|
33ca981684f22d045dd7c064c0d26f2f3b5581b57177f62bfb364007236a73fe
|
What is the month and date mentioned in this letter, at the top ?
Offer a very short reply.
|
October 25.
|
docvqa
|
|
c4bf1766bf1d03e1bba31554689f6fb0efba2da4c2b20247061f180283629dd7
|
By whom is this document written?
Give a very brief answer.
|
Stacey Dixon Calahan.
|
docvqa
|
|
f65dd70ff23f091127b00fd9696caaf3d9e76835c0a1e3044fa1e9a26632a728
|
What is the date mentioned?
Your answer should be compact.
|
January 21, 1999.
|
docvqa
|
|
f65dd70ff23f091127b00fd9696caaf3d9e76835c0a1e3044fa1e9a26632a728
|
To whom is this document addressed?
Your answer should be very brief.
|
Mr. Larry Ellingson.
|
docvqa
|
|
f65dd70ff23f091127b00fd9696caaf3d9e76835c0a1e3044fa1e9a26632a728
|
By whom is this document written?
Your answer should be compact.
|
Kunio Iwatani.
|
docvqa
|
|
f65dd70ff23f091127b00fd9696caaf3d9e76835c0a1e3044fa1e9a26632a728
|
What is written in big bold letters at the bottom?
Ensure brevity in your answer.
|
DALY 19.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
To which department it belongs to ?
Give a very brief answer.
|
Department of health and human services.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
What is the date of submission?
Your response must be concise.
|
11/18/2002.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
What is the telephone number (include area code)?
Give a very brief answer.
|
847-383-3739.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
What is the serial number mentioned in the form?
Your answer should be very brief.
|
5 0 1.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
What is the expiration date ?
Your answer should be very brief.
|
November 30, 2002.
|
docvqa
|
|
7df3890e863bf54b456a43da57153bd8cdc3925e8764d5174be125dec5b5abb5
|
What is the name of the sponsor ?
Provide a short and direct response.
|
Takeda Pharmaceuticals North America, Inc.
|
docvqa
|
|
cd41a893f20e179f2ab5059d48a80810642f1b318ffcca310bf281f2b7d21f04
|
What has to be investigated before starting pioglitazone therapy?
Your answer should be compact.
|
Any macroscopic haematuria.
|
docvqa
|
|
cd41a893f20e179f2ab5059d48a80810642f1b318ffcca310bf281f2b7d21f04
|
What has been experienced commonly in patients taking actos in combination with insulin?
Offer a terse response.
|
Heart failure.
|
docvqa
|
|
cd41a893f20e179f2ab5059d48a80810642f1b318ffcca310bf281f2b7d21f04
|
Which medicine is used to treat type 2 diabetes mellitus?
Provide a short and direct response.
|
Actos/Competact.
|
docvqa
|
|
cd41a893f20e179f2ab5059d48a80810642f1b318ffcca310bf281f2b7d21f04
|
How many cases of bladder cancer from 12506 patients were reported?
Give a very brief answer.
|
19 cases.
|
docvqa
|
|
d5076c0a285018f9b8d0f2d138036c6e1895715ebbadd22a237fc563afa2e23b
|
Which foundation is mentioned in this document?
Keep it short and to the point.
|
The Cleveland Clinic Foundation.
|
docvqa
|
|
d5076c0a285018f9b8d0f2d138036c6e1895715ebbadd22a237fc563afa2e23b
|
Under which department , The Cleveland Clinic Foundation operates?
Offer a terse response.
|
Department of Cardiovascular Medicine.
|
docvqa
|
|
d5076c0a285018f9b8d0f2d138036c6e1895715ebbadd22a237fc563afa2e23b
|
What is the PO Box number?
Your answer should be very brief.
|
931535.
|
docvqa
|
|
d5076c0a285018f9b8d0f2d138036c6e1895715ebbadd22a237fc563afa2e23b
|
What is the Tax ID mentioned in this document?
Your answer should be compact.
|
34-0714585.
|
docvqa
|
|
10bf9264c86882139d552f4194cf184b7f3be53ee27e082ace6a53c7c0866c93
|
What is the ind mumber (if previously assigned ) ?
Make the answer very short.
|
33,729.
|
docvqa
|
|
10bf9264c86882139d552f4194cf184b7f3be53ee27e082ace6a53c7c0866c93
|
What is the serial number mentioned in the form?
Your answer should be very brief.
|
4 9 7.
|
docvqa
|
|
10bf9264c86882139d552f4194cf184b7f3be53ee27e082ace6a53c7c0866c93
|
What is the date of submission ?
Your answer should be compact.
|
11/1/02.
|
docvqa
|
|
10bf9264c86882139d552f4194cf184b7f3be53ee27e082ace6a53c7c0866c93
|
What is the name(s) of drug (include all available names: trade , generic, chemical, code)?
Keep it short and to the point.
|
ACTOS (pioglitazone HCI).
|
docvqa
|
|
10bf9264c86882139d552f4194cf184b7f3be53ee27e082ace6a53c7c0866c93
|
What is the form approved : omb no
Your answer should be very brief.
|
0910-0014.
|
docvqa
|
|
85e33448adcbf6e95f4fb396ba23b272d1c8f1e5fedbfa225e2e60e4cb30d60b
|
What is the word written in bold on the top of the document?
Provide a short and direct response.
|
Takeda.
|
docvqa
|
|
85e33448adcbf6e95f4fb396ba23b272d1c8f1e5fedbfa225e2e60e4cb30d60b
|
What is the date mentioned?
Provide a short and direct response.
|
19th January 2012.
|
docvqa
|
|
85e33448adcbf6e95f4fb396ba23b272d1c8f1e5fedbfa225e2e60e4cb30d60b
|
To whom was this letter written?
Your answer should be compact.
|
Healthcare Professional.
|
docvqa
|
|
bc98c79ea598d2f69901d08c6e62c02c4321a86e0900350f9f84301974a3e61e
|
What is the name of pharmaceuticals ?
Give a very brief answer.
|
TAkeda pharmaceuticals North America ,INc.
|
docvqa
|
|
bc98c79ea598d2f69901d08c6e62c02c4321a86e0900350f9f84301974a3e61e
|
To whom this letter is written ?
Ensure brevity in your answer.
|
Ms. Haskins.
|
docvqa
|
|
bc98c79ea598d2f69901d08c6e62c02c4321a86e0900350f9f84301974a3e61e
|
When did Regulatory affairs department receive this letter?
Keep it short and to the point.
|
JUN 16 2003.
|
docvqa
|
|
bc98c79ea598d2f69901d08c6e62c02c4321a86e0900350f9f84301974a3e61e
|
To whom a copy of cover letter has to be sent ?
Offer a terse response.
|
Ms. Jens Weber.
|
docvqa
|
|
9fe2c27d8b87b649d97165b304f8ea6c9fe67abfd75a8699b26d4cda213e9cfd
|
What is the fifth point?
Provide a succinct answer.
|
WAC and AWP generally;.
|
docvqa
|
|
9fe2c27d8b87b649d97165b304f8ea6c9fe67abfd75a8699b26d4cda213e9cfd
|
Education grants regarding which products?
Keep it short and to the point.
|
TPNA.
|
docvqa
|
|
9fe2c27d8b87b649d97165b304f8ea6c9fe67abfd75a8699b26d4cda213e9cfd
|
What is the date this document was last printed?
Offer a very short reply.
|
11/30/2012.
|
docvqa
|
|
9fe2c27d8b87b649d97165b304f8ea6c9fe67abfd75a8699b26d4cda213e9cfd
|
Which reimbursement for TPNA pharmaceutical products is generally given?
Your answer should be very brief.
|
Medicare and Medicaid.
|
docvqa
|
|
feee23762daaf8dffebbbf58293ce8eeedb158f12b5359a31a2c8932cb0dace0
|
What is the designation of Alfonso T. Perez, M.D.?
Offer a terse response.
|
Vice President, Clinical Research.
|
docvqa
|
|
feee23762daaf8dffebbbf58293ce8eeedb158f12b5359a31a2c8932cb0dace0
|
By whom was this agreement Agreed and Accepted?
Your answer should be very brief.
|
Richard A. Rudick, M.D.
|
docvqa
|
|
feee23762daaf8dffebbbf58293ce8eeedb158f12b5359a31a2c8932cb0dace0
|
What is the full form of FAR?
Give a very brief answer.
|
Federal Acquisitions Regulation.
|
docvqa
|
|
feee23762daaf8dffebbbf58293ce8eeedb158f12b5359a31a2c8932cb0dace0
|
What is the date of the signature of the chairman of the Division of clinical research?
Give a very brief answer.
|
5/8/07.
|
docvqa
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.